Empowering the Freelance Economy

Pfizer-BioNTech Vaccine to be made available next week

The UK government has authorised the first COVID-19 vaccine on independent advice of its medicines regulator, leading to the first vaccines to become available next week, the government has reported today.

The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech’s COVID-19 vaccine for use.

“This follows months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that the vaccine has met its strict standards of safety, quality and effectiveness,” a Department of Health and Social Care spokesperson has said.

The Joint Committee on Vaccinations and Immunisations (JCVI) will shortly publish its final advice for the priority groups to receive the vaccine, including care home residents, health and care staff, the elderly and the clinically extremely vulnerable.

“The vaccine will be made available across the UK from next week,” said the spokesperson. “The NHS has decades of experience in delivering large scale vaccination programmes and will begin putting their extensive preparations into action to provide care and support to all those eligible for vaccination.”

“To aid the success of the vaccination programme it is vital everyone continues to play their part and abide by the necessary restrictions in their area so we can further suppress the virus and allow the NHS to do its work without being overwhelmed.

“Further details will be set out shortly.”

The Freelance Informer published a report earlier today highlighting that the UK has become the first country in the West to approve a COVID vaccine for deployment.

COVID-19 Vaccine Update: UK medical regulator could approve COVID vaccines before the US; Cambridge University Hospital staff to be vaccinated this week; take part in a COVID vaccine trial – Freelance Informer

Leave A Reply

Your email address will not be published.